Committed to helping you meet the evolving challenges and opportunities in patient care.

Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Patients’ journeys inspire our work and drive our commitment.

We’re engaging with industry thought leaders to explore how science and innovation advance healthcare.

We are a community of diverse professionals working together to drive better healthcare options.

Enriching the communities where we live and work.

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

We are proud of our strong commitment to maintaining the highest standards of corporate governance.

Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Helping you reach a healthy life, full of possibility.

Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

​Innovation is at our core.  For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

1931: Drs. Ralph Falk and Don Baxter launched the Don Baxter Intravenous Products Corporation, the first commercial manufacturer of prepared IV solutions.

Not long after our founding, we introduced the TRANSFUSO-VAC container for blood collection and storage, which made blood banking practical and allowed storage for up to 21 days. 

By the decade’s end, we changed our name to Baxter Laboratories, Inc. and opened our first manufacturing facility in a renovated automobile showroom in Glenview, Illinois.

1941: We introduced the PLASMA-VAC container, which for the first time allowed plasma to be separated from whole blood for storage.

1948: We launched an unbreakable plastic container for blood storage.

1950: Our second U.S. manufacturing facility opened in Cleveland, Mississippi. Two years later, we became the first U.S. company to make commercially available human plasma following our acquisition of Hyland Laboratories.

1954: We went international, opening an office in Belgium. Two years later, Dutch physician Willem Kolff developed the first “artificial kidney,” which was made from wood slats, orange juice cans and a cellophane membrane. Building from his work, we produced the first commercial dialysis system later that year.

1960: We introduced the first peritoneal dialysis (PD) solution. PD filters waste from the blood of people in renal failure through their peritoneal membrane rather than an external dialyzer. A year later, we began trading on the New York Stock Exchange.

1970: We introduced Viaflex, the first flexible, plastic IV container. This medical breakthrough allowed infusions within a closed system, which reduced the chance for contamination.

1971: Our company joined the Fortune 500 list of the largest American corporations. We also opened an IV solutions manufacturing facility in North Carolina – to this day one of our largest.

Our Mini-bag plastic containers came on market in 1974, making ready-to-use premixed drugs available to hospitals. We moved to our current headquarters in Deerfield, Illinois, the next year.

We launched several products in the 1980s, including the InfusOR pump, which allowed patients to receive IV therapy in any setting.

1985: We acquired American Hospital Supply Corporation, a healthcare distribution company.   

1991: Our Interlink IV Access System launched, introducing the first “needleless” system for IV therapy.

1994: Homechoice, our automated peritoneal dialysis (APD) system, launched. We also opened a plant in Singapore to make peritoneal dialysis solutions for the Asian market.

1998: Our acquisition of Ohmeda’s Pharmaceutical Products Division made Baxter a leader in inhaled anesthetics.  That same year, we introduced the first triple-chamber flexible container for total parenteral nutrition and gained approval for our Tisseel product, the first fibrin sealant in the U.S.   

The early part of the decade was notable for a series of regulatory clearances for some of our core products. These included:

2007: We introduced V-Link, the first IV connector with an antimicrobial coating. A few years later, we received FDA clearance for Artiss, the first commercially available slow-setting fibrin sealant used to adhere skin grafts in burn patients.

2011: Baxter Ventures launched and became a new way for us to identify and fund healthcare innovation. We also acquired Baxa Corporation to enhance our pharmacy automation offerings.

2012: We acquired Sigma, a manufacturer of smart infusion pumps, and Synovis Life Technologies, Inc., a leading microsurgery products company.

2013: We acquired GAMBRO AB, a global innovator in renal care. We also received European Union marketing approval for Hemopatch Sealing Hemostat, which helps control bleeding in a variety of surgical scenarios.

2015: We spun off our BioScience business to focus on hospital, nutrition, renal and surgical care. We also launched Amia with Sharesource, the first APD system with user-friendly features that help guide end-stage renal disease patients through home peritoneal dialysis (PD) therapy, while keeping them remotely connected with their healthcare providers.

2016: In Europe, we launched Numeta G13E, the only triple-chamber, ready-to-use parenteral nutrition system approved for preterm infants. Also, HDx enabled by our Theranova is a new dialysis therapy we are pioneering for patients with end-stage renal disease. The Theranova dialyzer features an innovative membrane, which provides an expanded hemodialysis therapy (HDx).

2017: New versions of our Floseal and Tisseel hemostatic agents launched. We expanded our presence in generic injectables through the acquisition of Claris Injectables Limited, a generic injectable pharmaceutical company and agreement with ScinoPharm for generic oncology drugs. We announced new research and clinical development collaborations with leading institutions including Mayo Clinic and Ramot at Tel Aviv University/Tel Aviv Sourasky Medical Center. 

2018: Our Kaguya APD system launched in Japan, reflecting local needs and demographics, and making it a viable treatment option for renal patients there. We launched PrisMax, our next-generation system for CRRT and OST; Spectrum IQ in the U.S. and Evo IQ infusion pump -- the first pump introduced outside the U.S. and Canada markets in more than a decade. We completed the acquisition of Recothrom and Preveleak from Mallinckrodt.

2019: We developed myKidneyPlan (CDK&Me), our first patient-centered education mobile application for kidney disease. We expanded our patient monitoring portfolio with the Starling Fluid Management Monitoring System through the acquisition of Cheetah Medical and forged a partnership with bioMerieux on AKI diagnostics. We launched Myxredlin, the first and only ready-to-use insulin for IV infusion, capping off the addition of seven premixed drugs since 2016.

2020: At the onset of the unprecedented COVID-19 pandemic, as a global leader we heightened our focus on the health and safety of our employees; increased supply of our life-sustaining medicines and medical devices; and provided philanthropic support to impacted communities we serve. Some of other milestones included partnering with COSMED, we received U.S. FDA clearance of Q-NRG+, a metabolic monitoring device utilizing indirect calorimetry technology that accurately measures a patient's calorie needs to help inform prescription and administration of nutrition therapy. Acquiring Seprafilm adhesion barrier from Sanofi, partnered with MediAware, a specialist in clinical big-data analytics, with the intent to support our development of next-generation infusion pump dose error reduction software and receiving regulatory approval in several countries for the Evo IQ Syringe Infusion System.

2021: Amid the continuing COVID-19 pandemic, Baxter BioPharma Solutions, a premier contract manufacturing organization, entered into agreements with Novavax and Moderna to provide fill/finish sterile manufacturing services and supply packaging of COVID-19 vaccines. We also partnered with bioMérieux, a global leader in in vitro diagnostics to offer the NEPHROCLEAR™ CCL14 Test in Western Europe. The test is designed to predict persistent severe acute kidney injury and can be used to support timely clinical decision-making and care pathways. We accelerated the company's vision of transforming healthcare and advancing patient care worldwide — from the hospital to the home — with the acquisition of Hillrom. The company's largest acquisition provides more opportunities for innovation and enables broader access to care globally.

©Copyright 2022 Baxter. All rights reserved.